Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 3, 2023
Distillery Therapeutics

Dual IKZF2 and CSNK1A degrader for AML

BioCentury | Nov 11, 2022
Product Development

Molecular glue degraders: moving beyond IMiDs

Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Jan 12, 2018
Company News

Exelixis, StemSynergy in CSNK1A activator deal

BioCentury | Jul 18, 2017
Distillery Therapeutics

Cancer

BioCentury | May 16, 2016
Company News

Hebrew University of Jerusalem, BioTheryX deal

Items per page:
1 - 5 of 5
Help Center
Username
Request a Demo
Request Training
Ask a Question